natgillin/translations-raw huggingface dataset:
In addition to this, we recognized a new pharmacological effect of the combination; analgesia, which had not been acknowledged before concerning the individual use of the any of these drugs in the human therapy. 
Uz to, prepoznali smo novi farmakološki učinak kombinacije; analgezija, koja nije bila priznata prije razmatranja pojedinačne upotrebe svakog od tih lijekova u ljudskoj terapiji.
The compound 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, or a pharmaceutically acceptable salt thereof, according to claim 1 for use in the treatment of chronic obstructive pulmonary disease. 
Spoj, naznačen time, da je to 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, te time, da se on upotrebljava za liječenje kronične opstrukcijske plućne bolesti.
The water soluble taxane derivative according to claim 1, characterized in that R4 and R5 are each independently H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. 
Derivat taksana topiv u vodi u skladu s bilo kojim od patentnih zahtjeva 1- 4, naznačen time što su R* i R> svaki novisno H, metill, ethil, propil, izopropil, butil, izobutil, benzil, ciclopropil, ciclobutil, ciclopentil ili cicloheksil.
The collection of nucleic acids according to claim 13, wherein said antibodies or functional fragments thereof comprise CDR2 regions comprising germline protein sequences from the respective variable heavy chain and variable light chain pairs depicted in SEQ ID NOs: 204-216, 230-239 and 250-257. 
Zbirka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što navedena protutijela, ili njihovi funkcionalni fragmenti, sadrže područja CDR2 koja se sastoje od sljedova proteina iz zametne linije iz odgovarajućih parova varijabilnih teških lanca s varijabilnim lakim lancima.
The device of clause 6 wherein said heat energy unit comprising electromagnetic element to provide electromagnetic energy to said substance by induction heating mechanism. 
Sustav iz patentnog zahtjeva 2, naznačen time, da navedeni grijaći uređaj sadrži elektromagnetski element koji osigurava elektromagnetsku energiju spomenutoj tvari pomoću indukcijskog mehanizma za grijanje.
The compound of claim 1 having Formula (IIa): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein: ring A is independently selected from 
Spoj iz patentnog zahtjeva 1 koji ima Formulu (Ila): ie ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje: prsten A je nezavisno bo od
The energy source can comprise a condensable vapor source. The ablation probe can be further adapted and configured to be advanced through a urethral wall and into an apex of the prostate lobe. 
Sustav prema zahtjevu 1, naznačen time da je sonda za ablaciju (120) nadalje podešena i konfigurirana za postavljanje kroz stjenku uretre i u vrh režnja prostate.
The pediculicide as claimed in claim 3 wherein the organophosphate or carbamate is present in a first pediculicide composition at a concentration of 0.02 to 0.4% wt.. 
Pedikulicid u skladu s patentnim zahtjevom 3, naznačen time što je organofosfat ili karbamat prisutan u prvom pedikulicidnom pripravku u koncentraciji od 0,02 do 0,4%, težinski.
Another instance describes a compound of formula (I) having the structure of formula (I-M): 
Spoj sukladno patentnom zahtjevu 6, formule (I-M): he
The peptide according to any one of claims 1 to 3 or an activated cytotoxic T lymphocyte according to claim 10 for use according to claim 11 in the form of a cancer vaccine. 
Peptid u skladu s bilo kojim patentnim zahtjevom 1 - 4, stanica u skladu s patentnim zahtjevom 7, ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11 za uporabu u skladu s patentnim zahtjevom 12 u obliku cjepiva protiv karcinoma.
The drying was continued sieving through a sieve of 1.2x1.2 mm every hour. 
Sušenje je nastavljeno prosijavanjem kroz sito dimenzija 1,2 x 1,2 mm svakih sat vremena.
Resistor 111, which in fig. 2 was shown connected directly to LED diode 112, now is connected to the node where the cathodes of diodes 310, 312 join; a conductor 320 connects the center-tap of secondary 330 of transformer 300 to LED diode 112, to which a resistor 111b having a relative high value (about 10kΩ) is added in parallel. 
Otpornik 111, koji je na slici 2 prikazan kao direktno spojen na LED diodu 112, sada je spojen na točku gdje su spojene katode dioda 210, 312; vodič 320 spaja klizač sekundara transformatora 330 transformatora 300 s LED diodom 112 s kojom je u paralelu spojen otpornik 111b relativno visoke vrijednosti (oko 10 kQ).
Typically, in the process for producing the mixed-halide perovskite, the perovskite is a perovskite compound of formula (II): 
Miješani halid perovskit u skladu s patentnim zahtjevom 20, naznačen time, da je perovskit spoja formule (Ila):
A method comprising the steps of: precipitating a cryo-poor plasma fraction, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 6.7 and about 7.3 to obtain a supernatant enriched in IgG, 
taloženje kriosiromašne frakcije plazme, u prvom koraku taloženja, s oko 6% do oko 10% alkohola uz pH-vrijednost između oko 7,0 i oko 7,5, za dobivanje prvog taloga i prvoga dijela koji pliva na površini;
International Patent Application Serial No. 
Broj europske prijave patenta:
Package according to anyone of claims 1 to 29, characterised in that the package (1; 80; 90; 100) contains tobacco-related articles, wherein the tobacco-related articles are selected from the following group: cigarettes, cigarillos, cigars, tobacco-containing rods, smokeless tobacco, simulated smoking devices, inhalors without combustion of tobacco, aroma reservoirs. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 39, naznačen time što omot za pakiranje (1; 80; 90; 100; 110) sadržava proizvode koji su vezani uz duhan, pri čemu su proizvodi koji su vezani uz duhan odabrani iz sljedećih skupina: cigarete, cigarilosi, cigare, šipke koje sadržavaju duhan, duhan bez dima, naprave za simuliranje pušenja, naprave za inhaliranje bez izgaranja duhana, spremnici s aromama.
The composite material according to claim 1, wherein the composite material includes less than 4% by weight of solvents and/or water. 
Kompozitni materijal prema patentnim zahtjevima 5-6, naznačen time da sadrži manje od 4 % (w/w) otapala i/ili vode
The compound of any one of claims 1-3 wherein at least one of E1a and E1b is -N(H)(alkoxycarbonyl). 
Spoj iz bilo kojeg od patentnih zahtjeva 1-3 gdje najmanje jedno od E'* i E'" je -N(H)(alkoksikarbonil).
A solution of N-(t-butyloxycarbonyl)cyclohexylglycine (2.0 g, 7.77 mmol) in anhydrous THF (10 mL) was cooled to 0° C. Borane solution (1 M in THF, 15.5 mL, 15.5 mmol) was added slowly and the reaction mixture was warmed to room temperature and stirred for 2 hours. 
Otopinu N-(t-butiloksikarbonil)cikloheksilglicina (2,0 g, 7,77 mmol) u bezvodnom THF-u (10 ml) ohladi se na 0%C. Polako se doda otopina borana (1 M u THF-u, 15,5 ml, 15,5 mmol), a reakcijsku smjesu zagrije na sobnu temperaturu, te miješa 2 sata.
means (702-0) for outer encoding the PLP data; means (303) for a Low-Density Parity-Check, LDPC, encoding the outer encoded PLP data, for forward error correction and outputting, a forward error correction Frame, FEC Frame, of the LDPC encoded PLP data; 
Physical Layer Pipe, PLP) za prenošenje toka usluge, a uređaj obuhvaća: sredstva (702-0) za vanjsko kodiranje PLP podataka; sredstva (303) za provjeru parnosti niske gustoće (eng.
The oil according to any of the claims 4 to 12 wherein, in the case where several flavourings are used, the amount of flavourings added to the product is comprised of between 0.03% and 0.2% by weight, preferably between 0.05% and 0.15% by weight, with respect to the weight of the other components. 
Ulje prema jednom od zahtjeva 4 do 12, naznačeno time, da su aromatski dodaci u sadržaju od 0,03 do 0,2 masenih %, poželjno od 0,05 do 0,15 masenih %, u odnosu na masu ostalih sastojaka, u slučaju uporabe nekoliko aromatskih dodataka u proizvodu.
The bispecific antibody according to any one of clauses 28-43, which comprises a first human IgG2 constant region with amino acid substitutions at positions 236 and 278, wherein the amino acids are lysine, and a second human IgG2 constant region with amino acid substitutions at positions 249 and 288, wherein the amino acids are glutamate or aspartate. 
HR P20190044 T1 od SEQ ID NO: 42, pri čemu su aminokiseline zamijenjene s glutamatom i aspartatom, i drugo ljudsko konstantno područje IgG2 s aminokiselinskim supstitucijama na pozicijama koje odgovaraju pozicijama 236 i 278 od SEQ ID NO: 42, pri čemu su aminokiseline zamijenjene s lizinom.
a flow rate of said pump, and 
brzine protoka kroz navedenu crpku, i -
An Anabaena variabilis phenylalanine ammonia-lyase (Av-PAL) variant wherein the cysteine residues at positions 503 and 565 of AvPAL have been substituted with serine residues (SEQ ID. 
AVvPAL varijanta, naznačena time, da su cisteinski ostaci na položajima 503 i 565 AvPAL- a supstituirani serinskim ostacima (SEQ ID.
Pd/C (1.8 mg) was added and the resulting mixture was stirred under a hydrogen atmosphere (balloon) for 24 hours. 
Pd/C (1.8 mg) se doda i rezultirajuća smjesa se miješa uz atmosferu vodika (balon) tijekom 24 sata.
The secondary drying is carried out at a temperature from about 20°C to about 30°C and a pressure of about 100 µbar for approximately 20 to 40 hours. 
Sekundarno sušenje je izvedeno na temperaturi od oko 20%C do oko 30fC i pritisku od oko 100 ubar približno 20 do 40 sati.
The amount of calcium (quantity of calcium) in the macrocyclic chelate used in step b) is advantageously less than 200 ppm and advantageously in the region of or less than 50 ppm and even preferably less than 15 ppm. 
Postupak prema zahtjevu 8, naznačen time da je količina kalcija u tekućoj farmaceutskoj formulaciji koja se daje pacijentu manja od 50 ppm i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu u koraku b), odnosno za DOTA prašak, vodi i megluminu, manja od 20 ppm, poželjno manja od 15 ppm.
The idler gear is mounted by an eccentric member to permit movement of the idler gear relative to the drive gear and driven gear to reduce backlash in the drive and gear assembly. 
Potporni zupčanik je smješten na ekscentričnom elementu kako bi omogućio njegovo pomicanje u odnosu na pogonski zupčanik i da smanji povratni trzaj u sustavu pogonskih zupčanika.
Supplied by Svenska Lantmännen, Tradename: RME 
SvenskaLantmannen, komercijalni naziv: RME,
After 30 min, the solid was filtered and dried to afford 2-4 as a solid (180 g); m.p. 
Nakon 30 min, krutina je filtirirana i osušena, da se dobije 2j4 kao krutina (180 g); m.p.
is piperidinyl substituted with 1 substituent selected from the group consisting of 
R' je piperidinil susptituiran sa 1 supstituentom izabranim iz grupe koju čine
The pooling device of embodiment 18, wherein said fluid connection assembly [104] includes a second force-activated valve [184] being connected to said inlet port of said pooling device for selectively regulating a directional fluid flow of the fluid. 
Uređaj za objedinjavanje prema zahtjevu 6, naznačen time što navedeni sklop za spajanje fluida [104] sadrži drugi ventil koji se aktivira silom [184] koji je spojen na navedeni ulazni otvor navedenog uređaja za objedinjavanje radi selektivnog reguliranja usmjerenog fluidnog strujanja fluida.
The method of item 6, wherein the cancer is lung cancer or colorectal cancer. 
Metoda sukladno patentnom zahtjevu 3, pri čemu se gore navedeni karcinom odnosi na karcinom pluća ili karcinom debelog crijeva.
Upon cooling, crystals formed which were stirred for 2 hours at 20°C, and subsequently collected by filtration, washed with a water: acetone (1:1) solution, and dried. 
Nakon hlađenja su nastali kristali koji su miješani 2 sata na 20"C 1 zatim sakupljeni filtracijom, isprani otopinom voda:aceton (1:1) solution, i osušeni.
The pharmaceutical dosage form for use according to any of the preceding claims, wherein the pharmacologically active agent according to general formula (I) has a stereochemistry according to general formula (I') wherein R is defined as in claim 1. 
Farmaceutski oblik doziranja za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što farmakološki aktivno sredstvo prema općoj formuli (I) ima stereokemiju prema općoj formuli (T) pri čemu je R definiran kao u patentnom zahtjevu 1.
A composition comprising a pharmaceutically acceptable amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Kompozicija koja sadrži farmaceutski prihvatljivu količinu spoja bilo kojeg od patentnih zahtjeva 1 do 9, ili farmaceutski prihvatljive soli tog spoja, i farmaceutski prihvatljiv nosač.
a CD3Z primary signaling domain. 
CD3 primarnu signalizacijsku domenu.
Throughout the specification and claims, reference to specific compounds refers to the racemates unless otherwise indicated. 
Unutar specifikacije i patentnih zahtjeva reference za specifične spojeve se odnose na racemate ukoliko nije drukčije navedeno.
The cell supernatant is collected and human IFN-Y measured by means of a specific immunoassay (ELISA h-IFN-Y, Duo Set R&D Systems kit). 
- >< Stanični supernatant se sakupi, a nakon toga se u njemu odredi ljudski INF-y s pomoću specifičnog imuno-testa (ELISA h-INF-y, Duo Set R&D Systems kit).
A compound of formula (VI), a salt, or stereoisomer thereof, wherein, 
Spoj formule (VI), njegova sol ili njegov stereoizomer O O
Generation of monoclonal antibodies of the invention 
Broj objave europskog patenta:
The composition for use in a method of treating cancer of claim 1, wherein the isolated monomeric platinum complex is (trans -1,2-cyclohexanediamine)- trans -dihydroxo(dihydrogen pyrophosphato)platinum(IV). 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)-trans-dihidrokso(dihidrogen pirofosfato)platina(IV).
The anti-IL-5 antibody for the use as claimed in claim 1, wherein said mean maximum plasma concentration is in the range of 12.1 ± 2.4 µg/mLto 278 ±29 µg/mLand/ or wherein said AUC(0-inf) is in the range of 207 ±34 µg×day/mL to 4361 ± 168 µg×day/mL. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je navedena srednja najveća koncentracija u plazmi u rasponu od 12,1 ± 2,4 µg/ml do 278 629 µg/ml i/ili što je navedeni AUC(0-∞) u rasponu od 207 634 µg×dan/ml do 4361 ± 168 µg×dan/ml.
The lectin protein of aspect 1 wherein said lectin has a molecular weight of approximate 16.1 kDa and PI value of 6.614 
Bjelančevina tipa lektin prema patentnom zahtjevu 1, naznačena time što navedeni lektin ima molekulsku masu približno 16,1 kDa 1 PI vrijednost od 6,614.
The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutical composition comprises from 20 mg to 40 mg, preferably 30 mg, 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one. 
Farmaceutski sastav za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da farmaceutski sastav sadrži od 20 mg do 40 mg, prvenstveno 30 mg 3a-hidroksi-35-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona.
The mixture of claim 7, wherein the antibody is derived from mammals, preferably from human, mice or rats. 
Mješavina prema zahtjevu 7, naznačena time što je antitijelo dobiveno od sisavaca, poželjno čovjeka, miševa 1li štakora.
While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. 
Kako je ovaj izum opisan u vezi sa specifičnim ustrojem istog, razumljivo je podložan daljnjim preinakama.
the compound of formula I is a compound of formula Im: or a salt thereof. 
ili njegova sol; ili pri čemu spoj formule I je spoj formule Im:
An oral immediate release pharmaceutical composition of claim 9, wherein the formulation releases in vitro, when measured using the Ph. 
Oralni farmaceutski sastav s trenutnim oslobađanjem prema zahtjevu 9, pri čemu formulacija oslobađa in vitro, izmjereno koristeći postupak s lopaticama prema Ph.
According to an embodiment, the composition for use is administered to the disc space of an intervertebral disc contributing to the intervertebral disc-related pain. 
Kompozicija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što se navedena kompozicija primjenjuje na prostor diska intervertebralnog diska koji doprinosi boli povezanoj s intervertebralnim diskom.
a coating on the surface of the inorganic particulate, wherein the coating comprises: a first compound including a terminating propanoic group or ethylenic group with one or two adjacent carbonyl groups, with the proviso that when the at least one polymer is not recycled from polymer waste in accordance with any one of paragraphs 1-13, the coating additionally comprises a second compound selected from the group consisting of one or more fatty acids and one more salts of a fatty acid, for example, stearic acid and/or calcium stearate. 
Polimerna smjesa, naznačena time što se sastoji od: najmanje jednog polimera; i funkcionalnog punila, koje uključuje: i. anorganski partikulat; 1 ii. obloga na površini anorganskog partikulata, gdje se obloga sastoji od: prvog spoja, koji sadrži krajnju propanskokiselinsku skupinu ili etilensku skupinu, uz jednu ili dvije susjedne karbonilne skupine, uz uvjet da kada se najmanje jedan polimer ne reciklira iz polimernog otpada u skladu s bilo kojim od patentnih zahtjeva 1-7, obloga dodatno sadrži drugi spoj, kojeg se bira iz skupine koju čine jedna ili više masnih kiselina i jedna ili više soli masnih kiselina, te njihove kombinacije; te gdje funkcionalno punilo dolazi u količini jednakoj ili većoj od 10%, težinski, polimera.
The method of paragraph 3, wherein the adverse reaction is thrombocytopenia, neutropenia or leucopenia. 
Postupak prema zahtjevu 1, pri čemu je neželjena reakcija trombocitopenija, neutropenija ili leukopenija.
is H or CH3; R2 is H or CH3; R3 is H; and one of R4 and R5 is H, and the other is -CH2-X, wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; wherein each phenyl or heteroaryl is optionally substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and -N(R')R'; 
Ri je H ili CHs; R> je H ili CH3; Rs je H; i jedan od Ry i Rs je H, i drugi je -CH>-X, pri čemu X je fenil ili heteroaril uključujući od 5 do 6 atoma prstena pri čemu su 1, 2, ili 3 od atoma prstena neovisno odabrani od skupine koja se sastoji od N, NH, N(C;-C: alkila), O 1 S; pri čemu je svaki fenil ili heteroaril izborno supstituiran s od 1-3 supstituenata neovisno odabranih od skupine koja se sastoji od halogena, cijano, C;- Ce alkila, hidroksila, Cy-Cg alkoksi i -N(R')R';
In another embodiment, in formula (VI), X42 is CR44; Y is CR43; and R43 and R44 together with the carbon atoms to which they are attached form a cycloalkenyl, an aryl, heterocyclyl, or heteroaryl ring. 
Spoj prema zahtjevu 19, pri čemu Xpje CR4y; Yao je CRg 1 R43 1 Ra zajedno sa ugljikovim atomima za koje su vezani čine cikloalkenil, aril, heterociklil ili heteroaril prsten.
The method according to claim 1, wherein a treatment of the fluid sample is used to remove interfering chemicals from the fluid immiscible with water. 
Postupak u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačen time, da se obrada tekućeg uzorka koristi za uklanjanje nepoželjnih tvari iz tekućine koja se ne miješa s vodom.
The oligonucleotide decoy of any one of claims 1 to 4 or the pharmaceutical composition of claim 5 for use in a method for treating or preventing pain in a patient, the method comprising administering to the patient a therapeutically effective amount of an oligonucleotide decoy of claims 1 to 4 or the pharmaceutical composition of claim 5. 
Oligonukleotidna zamka prema bilo kojem od zahtjeva 1 do 4, ili farmaceutski sastav prema zahtjevu 5, naznačen/a time, da se upotrebljava u postupku liječenja ili prevencije bolova kod pacijenta, pri čemu postupak obuhvaća davanje pacijentu terapeutski učinkovite količine oligonukleotidne zamke prema zahtjevima od 1 do 41li farmaceutskog sastava prema zahtjevu 5.
m is 0, 1 or 2, R11 is selected from hydrogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, aryl, substituted aryl heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle; 
m je 0, 1 ili 2; je odabran između vodika, hidroksila, C1-6-alkila, C1-6-alkoksi, arila, supstituiranog arila, heteroarila, supstituiranog heteroarila, heterocikla ili supstituiranog heterocikla;
Compound according to any one of items 1 to 12 in the treatment, prevention or amelioration of disorders in an animal, which disorder is treated, prevented or ameliorated by activation of an opioid receptor wherein the disorder is preferably selected from the group consisting of pain, diarrhea, or emesis. 
Spoj prema bilo kojem od zahtjeva 1 do 6 naznačen time da je za uporabu kod liječenja, sprečavanja ili ublažavanja poremećaja kod životinje, koji poremećaj se liječi, sprečava ili ublažava pomoću aktivacije opioidnog receptora.
The lamellas 3 and 4 overlap in the direction of their short side 6, over a distance which is practically equal to ⅔ to ⅚ of the length of this short side 6 . 
Lamele 3 i 4 se preklapaju u smjeru njihovih kraćih strana 6, duž razmaka koji je koji je praktički jednak 2/3 do 5/6 duljine kratke strane 6.
A process according to claim 8, wherein step b) is performed by addition of water to the reaction mixture. 
Postupak prema zahtjevu 8, gdje se korak a) provodi dodavanjem vode u reakcijsku smjesu.
It is also possible to mount T profiles on the bottom of the trolley 5 movable along the upper beam structures 4 and/or on the sides of the bogie structures 3, as shown in FIG. 
Sklop prema zahtjevu 1 ili 2, naznačen time što su T profili (9) postavljeni na dnu kolica (5) koje se pomiče duž gornjih greda (4) spojenih za podnožje (1) RTG dizalice na vrhu.
The method of claim 1, wherein the first nucleic acid, the second nucleic acid, or both nucleic acids comprise a bacterial artificial chromosome. 
prva nukleinska kiselina, druga nukleinska kiselina, ili obje nukleinske kiseline imaju najmanje10 kb; i/ili
The method of claim 2 in which p and q are both 0; or the pharmaceutically acceptable salt thereof. 
je odabran od vodika, fenila i naftila; gdje je navedeni fenil od R10 nesupstituiran ili supstituiran s metoksi; ili njegova farmaceutski prihvatljiva sol.
The piercer 11 is provided with a collar 25 extending from the lower abutment part towards the collapsible beverage container 2 on the outside of the support wall 20. 
Bušilo 11 ima prsten 25 koji ide iz donjeg ležajnog dijela prema sklopivom spremniku za piće 2 na vanjskoj nosećoj stijenci 20.
The operator would have to set control 70 based on empirical tests or calibration. 
Operater bi morao postaviti komandu 70 u položaj zasnovan na empirijskim provjerama ili kalibriranju.
The antibodies for the use of any one of claims 1-4, wherein the anti-PD-1 antibody is for being administered on Days 1, 15, 29, and 43 of each cycle. 
Antitijela za primjenu iz bilo kojeg od patentnih zahtjeva 1-4, gdje anti-PD-1 antitijelo je za administraciju na dane 1, 15, 29, 1 43 svakog ciklusa.
The compound or salt for use according to claim 1, wherein said cancer is cancer of the head and neck. 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je navedena bolest rak.